(Q38350489)

30 June 2019

review article

1 reference

title

Mechanisms and clinical significance of histone deacetylase inhibitors: epigenetic glioblastoma therapy (English)

1 reference

30 June 2019

1 reference

Philip Lee

1

1 reference

30 June 2019

Ben Murphy

2

1 reference

30 June 2019

Rickey Miller

3

1 reference

30 June 2019

Vivek Menon

4

1 reference

30 June 2019

Naren L Banik

5

1 reference

30 June 2019

Pierre Giglio

6

1 reference

30 June 2019

Scott M Lindhorst

7

1 reference

30 June 2019

Abhay K Varma

8

1 reference

30 June 2019

William A Vandergrift

9

1 reference

30 June 2019

Sunil J Patel

10

1 reference

30 June 2019

Arabinda Das

11

1 reference

30 June 2019

language of work or name

English

0 references

publication date

1 February 2015

1 reference

30 June 2019

published in

Anticancer Research

1 reference

30 June 2019

volume

35

1 reference

30 June 2019

issue

2

1 reference

30 June 2019

page(s)

615-625

1 reference

30 June 2019

Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs.

cites work

1 reference

12 December 2020

Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate

1 reference

12 December 2020

Role of autophagy in histone deacetylase inhibitor-induced apoptotic and nonapoptotic cell death

1 reference

12 December 2020

Antitumor effects of (S)-HDAC42, a phenylbutyrate-derived histone deacetylase inhibitor, in multiple myeloma cells.

1 reference

12 December 2020

The promise and failures of epigenetic therapies for cancer treatment

1 reference

12 December 2020

Histone deacetylase inhibitors in glioblastoma: pre-clinical and clinical experience

1 reference

12 December 2020

Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma

1 reference

12 December 2020

Synergistic killing of glioblastoma stem-like cells by bortezomib and HDAC inhibitors.

1 reference

12 December 2020

Histone deacetylase inhibitors such as sodium butyrate and trichostatin A induce apoptosis through an increase of the bcl-2-related protein Bad.

1 reference

12 December 2020

Identification of novel isoform-selective inhibitors within class I histone deacetylases

1 reference

12 December 2020

Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents

1 reference

12 December 2020

Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program

1 reference

12 December 2020

Catalytic activity and inhibition of human histone deacetylase 8 is dependent on the identity of the active site metal ion.

1 reference

12 December 2020

The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers

1 reference

12 December 2020

Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic

1 reference

12 December 2020

Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer

1 reference

12 December 2020

Histone deacetylases (HDACs): characterization of the classical HDAC family

1 reference

12 December 2020

Targeting histone deacetylases for the treatment of disease

1 reference

12 December 2020

Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study

1 reference

12 December 2020

Epigenetic cancer therapy: Proof of concept and remaining challenges

1 reference

12 December 2020

Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts

1 reference

12 December 2020

Up-regulation of p21(WAF1/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity

1 reference

12 December 2020

Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates

1 reference

12 December 2020

Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge

1 reference

12 December 2020

Plasma and cerebrospinal fluid pharmacokinetics of valproic acid after oral administration in non-human primates.

1 reference

12 December 2020

Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study

1 reference

12 December 2020

Is glioblastoma an epigenetic malignancy?

1 reference

12 December 2020

Valproic acid use during radiation therapy for glioblastoma associated with improved survival.

1 reference

12 December 2020

Histone deacetylase inhibitor AR42 regulates telomerase activity in human glioma cells via an Akt-dependent mechanism.

1 reference

12 December 2020

Genomic pathway analysis reveals that EZH2 and HDAC4 represent mutually exclusive epigenetic pathways across human cancers

1 reference

12 December 2020

The use of diversity profiling to characterize chemical modulators of the histone deacetylases

1 reference

12 December 2020

P53-dependent antiproliferative and pro-apoptotic effects of trichostatin A (TSA) in glioblastoma cells

1 reference

12 December 2020

HDAC inhibitor-based therapies: can we interpret the code?

1 reference

12 December 2020

Deacetylase inhibitors modulate proliferation and self-renewal properties of leukemic stem and progenitor cells.

1 reference

12 December 2020

Sodium butyrate sensitizes human glioma cells to TRAIL-mediated apoptosis through inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP.

1 reference

12 December 2020

Histone deacetylase inhibitors as therapeutics for polyglutamine disorders

1 reference

12 December 2020

The human histone deacetylase family

1 reference

12 December 2020

Phenylbutyrate sensitizes human glioblastoma cells lacking wild-type p53 function to ionizing radiation

1 reference

12 December 2020

Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas

1 reference

12 December 2020

Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas

1 reference

12 December 2020

Histone deacetylases: a saga of perturbed acetylation homeostasis in cancer

1 reference

12 December 2020

A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors.

1 reference

12 December 2020

The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid.

1 reference

12 December 2020

Multi-targeted DATS prevents tumor progression and promotes apoptosis in ectopic glioblastoma xenografts in SCID mice via HDAC inhibition

1 reference

12 December 2020

Molecular basis for the synergistic interaction of adriamycin with the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate (AN-9).

1 reference

12 December 2020

Histone deacetylase inhibition and blockade of the glycolytic pathway synergistically induce glioblastoma cell death

1 reference

12 December 2020

Is there a future for histone deacetylase inhibitors in the pharmacotherapy of psychiatric disorders?

1 reference

12 December 2020

CD81, a cell cycle regulator, is a novel target for histone deacetylase inhibition in glioma cells

1 reference

12 December 2020

Anticancer activities of histone deacetylase inhibitors

1 reference

12 December 2020

LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate

1 reference

12 December 2020

Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275.

1 reference

12 December 2020

Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed

1 reference

12 December 2020

Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect

1 reference

12 December 2020

Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage

1 reference

12 December 2020

A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03.

1 reference

12 December 2020

Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study

1 reference

12 December 2020

Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors

1 reference

12 December 2020

Complementary effects of HDAC inhibitor 4-PB on gap junction communication and cellular export mechanisms support restoration of chemosensitivity of PDAC cells

1 reference

12 December 2020

Understanding histone deacetylases in the cancer development and treatment: an epigenetic perspective of cancer chemotherapy

1 reference

12 December 2020

AN-113, a novel prodrug of 4-phenylbutyrate with increased anti-neoplastic activity in glioma cell lines

1 reference

12 December 2020

Valproic acid attenuates blood-brain barrier disruption in a rat model of transient focal cerebral ischemia: the roles of HDAC and MMP-9 inhibition.

1 reference

12 December 2020

Histone deacetylase inhibitors: overview and perspectives

1 reference

12 December 2020

Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks

1 reference

12 December 2020

The physiological roles of histone deacetylase (HDAC) 1 and 2: complex co-stars with multiple leading parts

1 reference

12 December 2020

Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights

1 reference

12 December 2020

In vivo and ex vivo assessment of the blood brain barrier integrity in different glioblastoma animal models

1 reference

12 December 2020

HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications

1 reference

12 December 2020

In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas

1 reference

12 December 2020

Histone deacetylase inhibitors such as sodium butyrate and trichostatin A inhibit vascular endothelial growth factor (VEGF) secretion from human glioblastoma cells

1 reference

12 December 2020

Glioblastoma multiforme: State of the art and future therapeutics

1 reference

12 December 2020

Histone deacetylase inhibitor, MS-275, exhibits poor brain penetration: PK studies of [C]MS-275 using Positron Emission Tomography

1 reference

12 December 2020

Histone deacetylase inhibitors: Potential in cancer therapy

1 reference

12 December 2020

Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications

1 reference

12 December 2020

Influence of valproic acid on outcome of high-grade gliomas in children.

1 reference

12 December 2020

Identifiers

PMCID

6052863

1 reference

30 June 2019

PubMed ID

25667438

1 reference

30 June 2019